LUX-Lung 2 and 3 cancer clinical trial James Yang
Afatinib* (compound code BIBW 2992) Mode of Action
Personalising cancer care and the future of cancer treatments John Heymach
Could new cancer targets change the outlook for personalised medicine? Kathleen Pritchard
LUX Lung clinical cancer trial programme Kenneth O'Byrne
Summary of LUX Lung 1 clinical trial Kenneth O'Byrne
Summary of LUX Lung 2 clinical trial Kenneth O'Byrne
Lung cancer and afatinib Federico Cappuzzo
Summary of LUX Lung 1 & 2 clinical trials Lucio Crino
Targeted cancer therapies
ErbB-Family Blockade and afatinib*
LUX-Lung 3 clinical trial infographic
LUX Lung 2 clinical trial infographic
Afatinib* Backgrounder
Epidermal growth factor (EGF) receptors
Irreversible binding of afatinib
Combined EGFR/HER1 and HER2 Inhibition
Pathways in EGFR and HER signaling
Mode of action afatinib* slide kit
Mutation detection with Quantitative Real Time PCR (Q-PCR)
LUX Lung 1 clinical trial
LUX Lung 1 clinical trial infographic
LUX Lung 1 clinical trial fact sheet
LUX Lung 2 clinical trial
LUX Lung 2 clinical cancer trial
LUX Breast 1 clinical trial
LUX Lung 3 clinical cancer trial
LUX Lung 4 clinical cancer trial
Lux lung 5 phase 3 clinical trial
Lux lung 6 cancer clinical trial
EGFR dysregulation and inhibition
Afatinib lung cancer trial results
Press Release LUX-Breast 1 Initiation September 2010
BIBW 2992 cancer treatment data presented at ASCO
Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
Boehringer Ingelheim to present new data on two lead oncology compounds at ASCO 2009
Boehringer Ingelheim and DxS sign agreement for a companion diagnostic test to identify EGFR mutations in patients with lung cancer
Press release Lux phase 3 BIBW 2992 (afatinib)
Could new cancer targets change the outlook for personalised medicine?
Afatinib (BIBW 2992) slide kit
Webcast South Korea, the evolution of lung cancer care
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.